SES Introduces Cruise Industry’s First Integrated MEO-LEO Service with Starlink
13.9.2023 09:50:00 EEST | Business Wire | Press release
For the first time ever, cruise operators can now depend on a single managed solution to reap the benefits of low-latency, high-throughput satellite connectivity services that are enabled by integrating Starlink’s low-earth orbit (LEO) and SES’s medium earth orbit (MEO) services, both companies announced today. The joint offering – SES Cruise mPOWERED + Starlink – seamlessly integrated, sold and delivered by SES – will combine the best of both MEO and LEO orbits to provide high-speed and secure connectivity 24/7 to cruise ships and their guests, regardless of their route and location.
Cruise operators will be able to enjoy SES's new offering that combines the truly global, high-throughput service of Starlink’s LEO system with SES’s unmatched performance MEO constellation to deliver a unique guest and crew experience by expanding existing capacity and reach. The solutions are available in either Premium tier (3Gbps/ship) – for the leading ships who wish to deliver the highest throughput in the industry or Pro tier (1.5Gbps/ship) – for the operators who wish to manage user experience by matching the right application to the right orbit.
As a managed service provider that pioneered multi-orbit geostationary (GEO) and MEO-enabled networks and delivered connectivity services directly to cruise operators for the last 10 years, SES’s partnership with SpaceX’s Starlink to add LEO-based service into its cruise offering, demonstrates a joint commitment to delivering the best customer experience to cruise operators and guests.
Investment in the cruise experience has reached new heights since the COVID-19 pandemic. Cruise operators are pushing technological and innovative boundaries, many of which are reliant on always-on, high-performance connectivity. This need is compounded by the growing expectations of cruise passengers and stakeholders alike to address the sector’s carbon emissions and comply with new maritime regulations, including CII and EEXI.
“At SES, we strive to provide a world-class connectivity experience for our cruise customers and deliver the same level of service they would enjoy on land,” said John-Paul Hemingway, Chief Strategy Officer at SES. “By being the only one in the cruise industry to expand our unique multi-orbit GEO and MEO network to utilise LEO, we believe it opens new opportunities for us to meet the needs of cruise guests and crew members, and the operational requirements of cruise operators to accelerate their digital transformations – wherever they may be.”
“We are excited to collaborate with SES on a joint solution that combines the reach and capacity of both satellite constellations to offer a solution unlike any other in the market,” said Chad Gibbs, SpaceX’s Vice President of Starlink Business Operations.
Available Q4 2023, SES Cruise mPOWERED + Starlink will fulfill the growing demands of cruise lines to deliver a superior guest experience, optimise smart ship operations, and attract and retain the best crew. With its fully managed end-to-end, best-in-industry bandwidth and low-latency performance, the solution will set an entirely new standard for ship connectivity worldwide and minimise upfront capital costs and ongoing operational expenditure.
To learn more about SES Cruise mPOWERED + Starlink packages, click here.
Follow us on:
Read our Blogs
>
Visit the Media Gallery
>
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 369 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912611179/en/
Contact information
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom